Interferon-γ brings additive anti-viral environment when combined with interferon-α in patients with chronic hepatitis C

Hepatology Research

Volumn 22, Issue 1, 2002, Pages 20-26

  Kumashiro, Ryukichi ^a   Ide, Tatsuya ^a   Sasaki, Masaru ^a   Murashima, Shiro ^a   Suzuki, Hiroshi ^a   Hino, Teruko ^a   Morita, Yasuyo ^a   Miyajima, Ichiro ^a   Ogata, Kei ^a   Tanaka, Eisuke ^a   Yoshida, Hiroshi ^b   Tanikawa, Kyuichi ^c   Sata, Michio ^a  

^a KURUME UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^b Yame General Hospital   (Japan)

^c International Institute for Liver Research   (Japan)

Author keywords

BMG; HCV RNA; Neopterin; sIL 12; Soluble (s) Fas

Indexed keywords

ALANINE AMINOTRANSFERASE; ALPHA INTERFERON; BETA 2 MICROGLOBULIN; CD4 ANTIGEN; CD8 ANTIGEN; FAS ANTIGEN; GAMMA INTERFERON; INTERLEUKIN 10; INTERLEUKIN 12; NEOPTERIN; TUMOR NECROSIS FACTOR ALPHA; VIRUS RNA;

ADULT; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ANTIVIRAL ACTIVITY; ARTICLE; BLOOD CELL; CHRONIC HEPATITIS; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CYTOKINE PRODUCTION; DRUG EFFICACY; DRUG POTENTIATION; FEMALE; GENOTYPE; HEPATITIS C; HUMAN; IMMUNOLOGICAL PARAMETERS; IMMUNOREGULATION; INTERFERON PRODUCTION; JAUNDICE; MALE; MONONUCLEAR CELL; PRIORITY JOURNAL; TH1 CELL;

EID: 0036119059     PISSN: 13866346     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1386-6346(01)00113-9     Document Type: Article

References (26)

1. Treatment of chronic viral hepatitis
2. Treatment of chronic hepatitis C with recombinant interferon alpha: A multicenter randomized, controlled trial
3. Meta-analysis of interferon randomized trials in the treatment of vural hepatitis C: Effects of dose and duration
4. Clinical efficacy of intramuscular human interferon-beta vs interferon-alpha 2b for the treatment of chronic hepatitis C
5. Limited humoral immunity in hepatitis C virus infection
6. Antibody responses to hepatitis C envelope proteins in patients with acute or chronic hepatitis C
7. Hepatitis C virus variants circumventing cytotoxic T lymphocyte activity as a mechanism of chronicity
8. Detection of type 2-like T-helper cells in hepatitis C virus infection: Implications for hepatitis C virus chronicity
9. CD30 induction and cytokine profiles in hepatitis C virus core-specific peripheral blood T lymphocytes
10. Natural interferon-gamma derived from lipopolysaccharide stimulated human myelo-monocytic HBL-28 cells
11. Expression of class I and class II major histocompatibility complex antigens on human hepatocytes
12. Decrease of interferon gamma serum levels in patients with chronic hepatitis C
13. Impairment of natural killer (NK) cytotoxic activity in hepatitis C virus (HCV) infection
14. Classification of chronic hepatitis: Diagnosis, grading and staging
15. Typing hepatitic C virus by polymerase chain reaction with wild type-specific primers: Application to clinical surveys and tracing infectious sources
16. Interleukin-1 a and interleukin-1β production in peripheral whole blood from patients with urological cancer
17. A pilot study of natural interferon gamma therapy for chronic hepatitis C
18. Possible mechanism involving T-lymphocyte response to non-structural protein 3 in viral clearance in acute hepatitis C virus infection
19. Different clinical behaviors of acute hepatitis C virus infection are associated with different vigor of the anti-viral cell-mediated immune response
20. Pathogenesis of chronic hepatitis C: Immunological features of hepatic injury and viral persistence
21. Interleukin-12 induction of Th 1 cytokines is important for viral clearance in chronic hepatitis B
22. Hepatitis C virus-specific T-cell reactivity during interferon and ribavirin treatment in chronic hepatitis C
23. Lamivudine treatment can restore T cell responsiveness in chronic hepatitis B
24. Progressive liver injury in chronic hepatitis C infection correlates with increased intrahepatic expression of Th1-associated cytokines
25. Interferon alfa-2b or in combination with ribavilin as initial treatment for chronic hepatitis C
26. Interferon alfa-2b alone or in combination with ribavirin for the treatment of relapse of chronic hepatitis C